1. Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment
- Author
-
Valentina Ciaravino, Luca Landoni, Paola Vallerio, Sara Cingarlini, Aldo Scarpa, Stefano Crosara, Elisabetta Grego, Silvia Ortolani, Riccardo De Robertis, Mirko D'Onofrio, Claudio Bassi, Andrea Ruzzenente, and Giampaolo Tortora
- Subjects
Male ,Cancer Research ,Contrast Media ,Antineoplastic Agents ,Blood volume ,Neuroendocrine tumors ,pancreatic neuroendocrine tumor ,perfusion ,030218 nuclear medicine & medical imaging ,predictive biomarkers ,Lesion ,03 medical and health sciences ,Perfusion CT ,everolimus ,0302 clinical medicine ,Biomarkers, Tumor ,medicine ,Humans ,Prospective Studies ,Neoplasm Metastasis ,Stage (cooking) ,Aged ,Everolimus ,business.industry ,Liver Neoplasms ,General Medicine ,Middle Aged ,medicine.disease ,Intensity (physics) ,Pancreatic Neoplasms ,Neuroendocrine Tumors ,Treatment Outcome ,Liver ,Oncology ,030220 oncology & carcinogenesis ,Time to peak ,Female ,medicine.symptom ,Tomography, X-Ray Computed ,Nuclear medicine ,business ,Perfusion ,medicine.drug - Abstract
Aim To evaluate modifications of perfusional parameters assessed by perfusion computed tomography (P-CT) of liver metastases (LM) from pancreatic neuroendocrine tumors (PanNETs) during everolimus treatment. Patients and methods All patients with LMs from G1-2 PanNETs undergoing everolimus treatment between January 2013 and January 2015 were prospectively evaluated with P-CT at baseline, and after 2 and 4 months of therapy. Size, perfusion, blood volume (BV), peak enhancement intensity (PEI) and time to peak for each lesion were calculated. Results A total of 33 LMs in nine patients with G1-2 PanNETs were prospectively evaluated: 23/33 (69.7%) were responders, 10/33 (30.3%) were non-responders. Among perfusional parameters, only numerical peak enhancement intensity values significantly differed between the two groups at baseline (p=0.043). BV increase was the most significant perfusional modification identifying responding lesions, even at an early stage of treatment, with a high positive predictive value (89.47%). Conclusion P-CT seems to be useful for prediction of response to everolimus of LMs from PanNETs.
- Published
- 2017
- Full Text
- View/download PDF